Oncology Clinical Research

NCT00431795

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

NCT00453635

Study With Docetaxel, Carboplatin and Herceptin Versus Vinorelbine and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

NCT00447967

Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients

NCT00758732

Docetaxel/Carboplatin Versus Docetaxel/Caelyx in Pretreated Patients With Ovarian Carcinoma

NCT00431613

Study of Docetaxel/Gemcitabine Followed by Chemo-radiotherapy (Chemo-RT), With or Without Consolidation Chemotherapy, in IIIA/IIIB Non Small Cell Lung Cancer (NSCLC)

NCT01024504

Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer

NCT00615758

Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV

NCT00614965

Irinotecan Plus Cisplatin vs Pemetrexed Plus Cisplatin as 2nd Line in NSCLC Stage IIIB/IV

NCT00564720

Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer

NCT00620971

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

NCT00635726

Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

NCT00705549

Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer

NCT00681876

Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

NCT00694200

Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer

NCT00718913

Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer

NCT00741195

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

NCT00741221

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

NCT00749567

Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer

NCT00753909

Paclitaxel, Carboplatin Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer

NCT00755170

Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer

NCT00755534

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

NCT01120158

Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer

NCT01120171

Myocet Plus Endoxan for Older Patients With Breast Cancer

NCT02179567

Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC

NCT01985841

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

NCT01713296

Pazopanib in Relapsed and Refractory Small Cell Lung Cancer

NCT01852578

Cabazitaxel in Relapsed and Metastatic NSCLC

NCT02251951

Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer

NCT02624726

Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment

NCT02771314

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC